Skip to main content

Advertisement

SpringerLink
Log in

Similarities and Differences in Hypertension Guidelines

The Need for One Roadmap to Lower Cardiovascular Risk

  • Editorial
  • Published:
High Blood Pressure & Cardiovascular Prevention Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Five-year findings of the hypertension detection and follow-up program: I. Reduction in mortality of persons with high blood pressure, including mild hypertension. Hypertension Detection and Follow-up Program Cooperative Group. JAMA 1979; 242: 2562–71

  2. MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease: part 1. Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335: 765–74

    Article  PubMed  CAS  Google Scholar 

  3. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease: part 2. Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827–39

    Article  PubMed  CAS  Google Scholar 

  4. van den Hoogen PC, Feskens EJ, Nagelkerke NJ, et al. The relation between blood pressure and mortality due to coronary heart disease among men in different parts of the world: Seven Countries Study Research Group. N Engl J Med 2000; 342: 1–8

    Article  PubMed  Google Scholar 

  5. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure: Collaborative Group on ACE Inhibitor Trials. JAMA 1995 May 10; 273(18): 1450–6

    Article  PubMed  CAS  Google Scholar 

  6. Flather MD, Yusuf S, Kober L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients: the ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 2000; 355: 1575–81

    Article  PubMed  CAS  Google Scholar 

  7. Pahor M, Psaty BM, Alderman MH, et al. Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a metaanalysis of randomised controlled trials. Lancet 2000; 356(9246): 1949–54

    Article  PubMed  CAS  Google Scholar 

  8. Blood Pressure Lowering Treatment Trialists’ Collaboration. Effect of angiotensin-converting enzyme inhibitors, calcium antagonists, and other blood pressure lowering drugs: results of prospectively designed overviews of randomized trials. Lancet 2000; 355: 1955–64

    Google Scholar 

  9. Wolf-Maier K, Cooper RS, Banegas JR, et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 2003; 289(18): 2363–9

    Article  PubMed  Google Scholar 

  10. Chobanian A, Bakris G, Black H, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560–71

    Article  PubMed  CAS  Google Scholar 

  11. European Society of Hypertension (ESH)/European Society of Cardiology (ESC) guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011–53

    Google Scholar 

  12. World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003; 21: 1983–92

    Google Scholar 

  13. Williams B, Poulter NR, Brown MJ, et al. for the British Hypertension Society (BHS) Guidelines. Guidelines of management of hypertension: report of the fourth working party on British Hypertension Society — BHS IV. J Hum Hypertens 2004; 18: 139–85

    Article  PubMed  CAS  Google Scholar 

  14. Khan NA, McAlister FA, Campbell NR, et al. The 2004 Canadian recommendations for the management of hypertension: part II. Therapy. Canadian Hypertension Education Program. Can J Cardiol 2004; 20(1): 41–54

    PubMed  Google Scholar 

  15. National Cholesterol Education Program (NCEP), Expert Panel on Detection, Evaluation, et al. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): final report. Circulation 2002; 106: 3143–421

    Google Scholar 

  16. American Diabetes Association. Hypertension management in adults with diabetes. Diabetes Care 2004; 27: S65–7

    Google Scholar 

  17. National Kidney Foundation. Clinical practice guidelines for hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004; 43: 65–230

    Google Scholar 

  18. Volpe M, Alderman MH, Furberg CD, et al. Beyond hypertension toward guidelines for cardiovascular risk reduction. Am J Hypertens. 2004; 17(11 Pt 1): 1068–74

    PubMed  Google Scholar 

  19. Alderman MH, Furberg CD, Kostis JB, et al. Hypertension guidelines: criteria that might make them more clinically useful. Am J Hypertens 2002; 15(10 Pt 1): 917–23

    Article  PubMed  Google Scholar 

  20. Vasan RS, Larson MG, Leip EP, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001; 345(18): 1291–7

    Article  PubMed  CAS  Google Scholar 

  21. Weber MA, Bakris GL, Neutel JM, et al. Quality of life measured in a practice-based hypertension trial of an angiotensin receptor blocker. J Clin Hypertens (Greenwich) 2003; 5: 322–9

    CAS  Google Scholar 

  22. Bloom BS. Continuation of initial antihypertensive medication after 1 year of therapy. Clin Ther 1998; 20: 671–81

    Article  PubMed  CAS  Google Scholar 

  23. Volpe M, Ruilope LM, McInnes GT, et al. Angiotensin-II receptor blockers: benefits beyond blood pressure reduction? J Hum Hypertens 2005; 19(5): 331–9

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The author has provided no information on sources of funding or on conflicts of interest directly relevant to the content of this editorial.

Author information

Authors and Affiliations

  1. Cardiology, II Faculty of Medicine, University of Rome “La Sapienza”, Sant’Andrea Hospital, Via di Grottarossa, Rome 1035-39, 00189, Italy

    Massimo Volpe

  2. IRCCS Neuromed, Pozzilli, Isernia, Italy

    Massimo Volpe

Authors
  1. Massimo Volpe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Massimo Volpe.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Volpe, M. Similarities and Differences in Hypertension Guidelines. High Blood Press Cardiovasc Prev 12, 63–66 (2005). https://doi.org/10.2165/00151642-200512020-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151642-200512020-00001

Search

Navigation